Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02210, USA; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA.
Cell. 2018 Feb 22;172(5):1007-1021.e17. doi: 10.1016/j.cell.2018.01.032.
MLL/SET methyltransferases catalyze methylation of histone 3 lysine 4 and play critical roles in development and cancer. We assessed MLL/SET proteins and found that SETD1A is required for survival of acute myeloid leukemia (AML) cells. Mutagenesis studies and CRISPR-Cas9 domain screening show the enzymatic SET domain is not necessary for AML cell survival but that a newly identified region termed the "FLOS" (functional location on SETD1A) domain is indispensable. FLOS disruption suppresses DNA damage response genes and induces p53-dependent apoptosis. The FLOS domain acts as a cyclin-K-binding site that is required for chromosomal recruitment of cyclin K and for DNA-repair-associated gene expression in S phase. These data identify a connection between the chromatin regulator SETD1A and the DNA damage response that is independent of histone methylation and suggests that targeting SETD1A and cyclin K complexes may represent a therapeutic opportunity for AML and, potentially, for other cancers.
MLL/SET 甲基转移酶催化组蛋白 3 赖氨酸 4 的甲基化,在发育和癌症中发挥关键作用。我们评估了 MLL/SET 蛋白,发现 SETD1A 是急性髓细胞白血病 (AML) 细胞存活所必需的。诱变研究和 CRISPR-Cas9 结构域筛选表明,酶 SET 结构域对于 AML 细胞存活不是必需的,但新鉴定的称为“FLOS”(SETD1A 上的功能位置)结构域是必不可少的。FLOS 结构域的破坏抑制了 DNA 损伤反应基因,并诱导 p53 依赖性细胞凋亡。FLOS 结构域作为 cyclin-K 结合位点,对于 cyclin K 在染色体上的募集以及 S 期与 DNA 修复相关的基因表达是必需的。这些数据表明,染色质调节剂 SETD1A 与 DNA 损伤反应之间存在联系,这种联系独立于组蛋白甲基化,并表明靶向 SETD1A 和 cyclin K 复合物可能为 AML 提供治疗机会,并且可能为其他癌症提供治疗机会。